journal
MENU ▼
Read by QxMD icon Read
search

Innovations in Clinical Neuroscience

journal
https://www.readbyqxmd.com/read/28210526/encephalopathy-or-psychosis
#1
Malathi Latha Perugula, Steven Lippmann
No abstract text is available yet for this article.
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210525/ransomware-minimizing-the-risks
#2
Justin Pope
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210524/sympathetic-nerve-entrapment-point-injection-as-an-antireflux-procedure-for-refractory-laryngopharyngeal-reflux-a-first-case-report-of-innovative-autonomic-regulation
#3
Sangsoo Lee, Chang Jin Oh, Jeong Won Seong
Surgical treatment is not suitable for laryngopharyngeal reflux that is refractory to proton pump inhibitors. We present a case of proton pump inhibitor-refractory laryngopharyngeal reflux that was successfully treated with sympathetic nerve entrapment point injection. The patient had previously been diagnosed with laryngopharyngeal reflux and treated with proton pump inhibitors for six months without substantial improvement. After sympathetic nerve entrapment point injection treatment, her reflux symptom index improved from 15 points to 1 point, and this response was maintained for six months...
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210523/complete-recovery-from-cardiac-arrest-caused-by-risperidone-induced-hypothermia
#4
Takahiko Nagamine
Hypothermia is a rare adverse effect of risperidone and is associated with ventricular arrhythmias, which may lead to intensive care unit admission and sometimes death. We describe a patient with schizophrenia who was taking risperidone and who, after falling into a hypothermic state, suffered cardiac arrest. Observations of the case and a brief literature review are provided.
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210522/acute-hyperglycemia-associated-with-psychotic-symptoms-in-a-patient-with-type-1-diabetes-mellitus-a-case-report
#5
Swapnajeet Sahoo, Aseem Mehra, Sandeep Grover
Although psychiatric manifestations in the form of delirium, confusional states, and psychosis have been commonly reported in relation to hypoglycemia, association of hyperglycemia with psychiatric manifestations has been less commonly reported. In this case report, we present the case of a 36-year-old woman suffering from Type 1 diabetes mellitus who developed recurrent episodes of psychosis following poor adherence to her insulin therapy, leading to significantly high levels of blood glucose. Adequate control of blood glucose levels by improving the adherence with insulin led to lack of recurrence of psychosis...
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210521/the-right-to-die-in-chronic-disorders-of-consciousness-can-we-avoid-the-slippery-slope-argument
#6
REVIEW
Rocco Salvatore Calabrò, Antonino Naro, Rosaria De Luca, Margherita Russo, Lory Caccamo, Alfredo Manuli, Alessia Bramanti, Placido Bramanti
Managing individuals with chronic disorders of consciousness raises ethical questions about the appropriateness of maintaining life-sustaining treatments and end-of-life decisions for those who are unable to make decisions for themselves. For many years, the positions fostering the "sanctity" of human life (i.e., life is inviolable in any case) have led to maintaining life-sustaining treatments (including artificial nutrition and hydration) in patients with disorders of consciousness, allowing them to live for as long as possible...
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27975002/delirium-or-dementia
#7
Steven Lippmann, Malathi Latha Perugula
No abstract text is available yet for this article.
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27975001/consent-to-treatment-of-minors-revisited
#8
Ann McNary
No abstract text is available yet for this article.
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27975000/cariprazine-for-schizophrenia-and-bipolar-disorder
#9
REVIEW
Jonathan R Scarff
Schizophrenia and bipolar disorder are associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms of schizophrenia as well as manic or mixed episodes of bipolar disorder, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. Cariprazine was recently approved to treat adult patients with schizophrenia and manic or mixed episodes. It was well-tolerated and adverse reactions included akathisia, extrapyramidal symptoms, nausea, or constipation...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974999/eszopiclone-induced-parasomnia-with-suicide-attempt-a-case-report
#10
J Gibson Pennington, Jeffrey Guina
Eszopiclone is a benzodiazepine-like hypnotic that is commonly prescribed to treat insomnia. However, eszopiclone's efficacy has been questionable in several clinical trials, and its pharmacologic profile makes its effects on sleep and behavior difficult to predict. We report a case demonstrating an instance of eszopiclone-induced parasomnia involving paranoia and a suicide attempt in a patient taking eszopiclone. We explore possible biochemical explanations examining the pharmacologic profile of eszopiclone and its potential for drug-drug interactions, especially with concomitant administration of monoaminergic medications such as antidepressants...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974998/assessment-of-cognitive-and-neurologic-recovery-in-ischemic-stroke-drug-trials-results-from-a-randomized-double-blind-placebo-controlled-study
#11
Franco Di Cesare, Jessica Mancuso, Brian Silver, Peter T Loudon
Objective. Ischemic stroke is a serious medical condition with limited therapeutic options. The evaluation of the therapeutic potential of novel pharmacological interventions is carried-out in Phase II trials. The study design, primarily intended to evaluate efficacy and safety, is a balance between utilizing as few patients as possible to minimize safety risk and enrolling sufficient patients to detect unambiguous efficacy signals. We sought to determine whether post-stroke recovery outcomes based on behavioral measures of cognitive and motor impairment yielded additional information beyond that of clinician-based methods...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974997/the-depression-inventory-development-workgroup-a-collaborative-empirically-driven-initiative-to-develop-a-new-assessment-tool-for-major-depressive-disorder
#12
REVIEW
Anthony L Vaccarino, Kenneth R Evans, Amir H Kalali, Sidney H Kennedy, Nina Engelhardt, Benicio N Frey, John H Greist, Kenneth A Kobak, Raymond W Lam, Glenda MacQueen, Roumen Milev, Franca M Placenza, Arun V Ravindran, David V Sheehan, Terrence Sills, Janet B W Williams
The Depression Inventory Development project is an initiative of the International Society for CNS Drug Development whose goal is to develop a comprehensive and psychometrically sound measurement tool to be utilized as a primary endpoint in clinical trials for major depressive disorder. Using an iterative process between field testing and psychometric analysis and drawing upon expertise of international researchers in depression, the Depression Inventory Development team has established an empirically driven and collaborative protocol for the creation of items to assess symptoms in major depressive disorder...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974996/performance-reliability-usability-and-safety-of-the-id-cap-system-for-ingestion-event-monitoring-in-healthy-volunteers-a-pilot-study
#13
Glen P Flores, Brian Peace, Tony C Carnes, Susan L Baumgartner, D Eric Buffkin, Neil R Euliano, Larry N Smith
Background: Nonadherence to prescribed medications is an important consideration in the clinical management of patients and in clinical research and drug development. The ID-Cap System is a novel technology that provides an objective measure of medication ingestion and enables real-time reporting of verified medication adherence data at the dose level. The ID-Cap System consists of an ingestible microsensor that is embedded in an oral dosage form and, once activated by stomach fluid, communicates digital messages to an external wearable reader to confirm ingestion...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672489/fahr-s-disease-or-fahr-s-syndrome
#14
Malathi Latha Perugula, Steven Lippmann
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672488/professional-liability-for-forensic-activities-liability-without-a-treatment-relationship
#15
Donna Vanderpool
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672487/a-case-of-treatment-resistant-depression-and-body-dysmorphic-disorder-the-role-of-electroconvulsive-therapy-revisited
#16
Ram S Mahato, Maria Chona P San Gabriel, Carrol T Longshore, David B Schnur
Body dysmorphic disorder is a common, often disabling condition, and is frequently comorbid with major depressive disorder. Selective serotonin reuptake inhibitors constitute first line set of somatic interventions but the management of refractory patients remains challenging. Electroconvulsive therapy, an often highly beneficial treatment for medication resistant-depression, is not considered an effective therapeutic alternative for treatment refractory body dysmorphic disorder. Here we present a 50-year-old woman with body dysmorphic disorder and comorbid major depressive disorder who remained incapacitated and suicidal despite several trials with selective serotonin reuptake inhibitors and antipsychotic medication...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672486/the-potential-role-of-t-helper-cell-22-and-il-22-in-immunopathogenesis-of-multiple-sclerosis
#17
REVIEW
Nazanin Arjomand Fard, Gholamreza Azizi, Abbas Mirshafiey
Multiple sclerosis is a complex disease with many different immune cells involved in its pathogenesis. Newly identified T helper cell 22 (Th22) is a subset of CD4(+) T cells with specific properties apart from other known CD4(+) T cell subsets with distinguished function and gene expression. Th22 cells are characterized by production of a distinct profile of effector cytokines, including interleukin (IL)-22, IL-13, and tumor necrosis factor-α (TNF- α). The frequency of Th22 and related cytokine IL-22 are increased in various autoimmune diseases...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672485/brexpiprazole-a-new-treatment-option-for-schizophrenia
#18
REVIEW
Jonathan R Scarff
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672484/pharmaceutical-innovation-in-the-treatment-of-schizophrenia-and-mental-disorders-compared-with-other-diseases
#19
Joanna P MacEwan, Seth Seabury, Myrlene Sanon Aigbogun, Siddhesh Kamat, Emma van Eijndhoven, Clement Francois, Crystal Henderson, Leslie Citrome
OBJECTIVES: The objectives of this study were to assess the level of private and public investment in research and development of treatments for schizophrenia and other mental disorders compared to other diseases in order to present data on the economic burden and pharmaceutical innovation by disease area, and to compare the level of investment relative to burden across different diseases. DESIGN: The levels of investment and pharmaceutical innovation relative to burden across different diseases were assessed...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672483/criminal-behavior-and-borderline-personality-correlations-among-four-measures
#20
Randy A Sansone, Martin Sellbom, Douglas A Songer
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"